1.1 Actinic Keratosis

ALDARA Cream is indicated for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults.

1.2 Superficial Basal Cell Carcinoma

ALDARA Cream is indicated for the topical treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults, with a maximum tumor diameter of 2.0 cm, located on the trunk (excluding anogenital skin), neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured.

The histological diagnosis of superficialbasal cell carcinoma should be established prior to treatment, since safety and efficacy of ALDARA Cream have not been established for other types of basal cell carcinomas, including nodular and morpheaform (fibrosing or sclerosing) types.

1.3 External Genital Warts

ALDARA Cream is indicated for the treatment of external genital and perianal warts/condyloma acuminata in patients 12 years or older.

1.4 Limitations of Use

ALDARA Cream has been evaluated in children ages 2 to 12 years with molluscum contagiosum and these studies failed to demonstrate efficacy [see Use in Specific Populations (8.4)] .

1.5 Unevaluated Populations

The safety and efficacy of ALDARA Cream in immunosuppressed patients have not been established.

ALDARA Cream should be used with caution in patients with pre-existing autoimmune conditions.

The efficacy and safety of ALDARA Cream have not been established for patients with Basal Cell Nevus Syndrome or Xeroderma Pigmentosum.

2.1 Actinic Keratosis

ALDARA Cream should be applied 2 times per week for a full 16 weeks to a defined treatment area on the face or scalp (but not both concurrently). The treatment area is defined as one contiguous area of approximately 25 cm 2(e.g., 5 cm × 5 cm) on the face (e.g., forehead or one cheek) oron the scalp. Examples of 2 times per week application schedules are Monday and Thursday, or Tuesday and Friday. ALDARA Cream should be applied to the entire treatment area and rubbed in until the cream is no longer visible. No more than one packet of ALDARA Cream should be applied to the contiguous treatment area at each application. ALDARA Cream should be applied prior to normal sleeping hours and left on the skin for approximately 8 hours, after which time the cream should be removed by washing the area with mild soap and water. The prescriber should demonstrate the proper application technique to maximize the benefit of ALDARA Cream therapy.

It is recommended that patients wash their hands before and after applying ALDARA Cream. Before applying the cream, the patient should wash the treatment area with mild soap and water and allow the area to dry thoroughly (at least 10 minutes).

Contact with the eyes, lips, and nostrils should be avoided.

Local skin reactions in the treatment area are common [see Adverse Reactions (6.1, 6.5)]. A rest period of several days may be taken if required by the patient's discomfort or severity of the local skin reaction. However, the treatment period should not be extended beyond 16 weeks due to missed doses or rest periods. Response to treatment cannot be adequately assessed until resolution of local skin reactions. Lesions that do not respond to treatment should be carefully re-evaluated and management reconsidered.

ALDARA Cream is packaged in single-use packets, with 12 packets supplied per box. Patients should be prescribed no more than 36 packets for the 16-week treatment period. Unused packets should be discarded. Partially used packets should be discarded and not reused.

2.2 Superficial Basal Cell Carcinoma

ALDARA Cream should be applied 5 times per week for a full 6 weeks to a biopsy-confirmed sBCC. An example of a 5 times per week application schedule is to apply ALDARA Cream, once per day, Monday through Friday. ALDARA Cream should be applied prior to normal sleeping hours and left on the skin for approximately 8 hours, after which time the cream should be removed by washing the area with mild soap and water. The prescriber should demonstrate the proper application technique to maximize the benefit of ALDARA Cream therapy.

It is recommended that patients wash their hands before and after applying ALDARA Cream. The patient should wash the treatment area with mild soap and water before applying the cream, and allow the area to dry thoroughly.

The target tumor should have a maximum diameter of 2 cm and be located on the trunk (excluding anogenital skin), neck, or extremities (excluding hands and feet). The treatment area should include a 1 cm margin of skin around the tumor. Sufficient cream should be applied to cover the treatment area, including 1 cm of skin surrounding the tumor. ALDARA Cream should be rubbed into the treatment area until the cream is no longer visible.

Contact with the eyes, lips, and nostrils should be avoided.

Local skin reactions in the treatment area are common [see Adverse Reactions (6.2, 6.5)]. A rest period of several days may be taken if required by the patient's discomfort or severity of the local skin reaction.

Early clinical clearance cannot be adequately assessed until resolution of local skin reactions (e.g., 12 weeks post-treatment). Local skin reactions or other findings (e.g., infection) may require that a patient be seen sooner than the post-treatment assessment for clinical clearance. If there is clinical evidence of persistent tumor at the post-treatment assessment for clinical clearance, a biopsy or other alternative intervention should be considered. Lesions that do not respond to therapy should be carefully re-evaluated and management reconsidered; the safety and efficacy of a repeat course of ALDARA Cream treatment have not been established. If any suspicious lesion arises in the treatment area at any time after a determination of clinical clearance, the patient should seek a medical evaluation [see Clinical Studies (14.2)] .

ALDARA Cream is packaged in single-use packets, with 12 packets supplied per box. Patients should be prescribed no more than 36 packets for the 6-week treatment period. Unused packets should be discarded. Partially used packets should be discarded and not reused.

2.3 External Genital Warts

ALDARA Cream should be applied 3 times per week to external genital/perianal warts. ALDARA Cream treatment should continue until there is total clearance of the genital/perianal warts or for a maximum of 16 weeks. Examples of 3 times per week application schedules are: Monday, Wednesday, Friday or Tuesday, Thursday, Saturday. ALDARA Cream should be applied prior to normal sleeping hours and left on the skin for 6 –10 hours, after which time the cream should be removed by washing the area with mild soap and water. The prescriber should demonstrate the proper application technique to maximize the benefit of ALDARA Cream therapy.

It is recommended that patients wash their hands before and after applying ALDARA Cream.

A thinlayer of ALDARA Cream should be applied to the wart area and rubbed in until the cream is no longer visible. The application site should not be occluded. Following the treatment period, the cream should be removed by washing the treated area with mild soap and water.

Local skin reactions at the treatment site are common [see Adverse Reactions (6.3, 6.5)] . A rest period of several days may be taken if required by the patient's discomfort or severity of the local skin reaction. Treatment may resume once the reaction subsides. Non-occlusive dressings such as cotton gauze or cotton underwear may be used in the management of skin reactions.

ALDARA Cream is packaged in single-use packets which contain sufficient cream to cover a wart area of up to 20 cm 2; use of excessive amounts of cream should be avoided.

5.1 Local Inflammatory Reactions

Intense local inflammatory reactions including skin weeping or erosion can occur after a few applications of ALDARA Cream and may require an interruption of dosing [see Dosage and Administration (2), Adverse Reactions (6)] . ALDARA Cream has the potential to exacerbate inflammatory conditions of the skin, including chronic graft versus host disease.

Severe local inflammatory reactions of the female external genitalia can lead to severe vulvar swelling.

Severe vulvar swelling can lead to urinary retention. Dosing should be interrupted or discontinued for severe vulvar swelling.

Administration of ALDARA Cream is not recommended until the skin is completely healed from any previous drug or surgical treatment.

5.2 Systemic Reactions

Flu-like signs and symptoms may accompany, or even precede, local inflammatory reactions and may include malaise, fever, nausea, myalgias, and rigors. An interruption of dosing should be considered [see Adverse Reactions (6)].

5.3 Ultraviolet Light Exposure

Exposure to sunlight (including sunlamps) should be avoided or minimized during use of ALDARA Cream because of concern for heightened sunburn susceptibility. Patients should be warned to use protective clothing (e.g., a hat) when using ALDARA Cream. Patients with sunburn should be advised not to use ALDARA Cream until fully recovered. Patients who may have considerable sun exposure, e.g., due to their occupation, and those patients with inherent sensitivity to sunlight should exercise caution when using ALDARA Cream.

ALDARA Cream shortened the time to skin tumor formation in an animal photococarcinogenicity study [see Nonclinical Toxicology (13.1)] . The enhancement of ultraviolet carcinogenicity is not necessarily dependent on phototoxic mechanisms. Therefore, patients should minimize or avoid natural or artificial sunlight exposure.

5.4 Unevaluated Uses: Actinic Keratosis

Safety and efficacy have not been established for ALDARA Cream in the treatment of actinic keratosis with repeated use, i.e., more than one treatment course in the same area.

The safety of ALDARA Cream applied to areas of skin greater than 25 cm 2(e.g., 5 cm × 5 cm) for the treatment of actinic keratosis has not been established [see Clinical Pharmacology (12.3)] .

5.5 Unevaluated Uses: Superficial Basal Cell Carcinoma

The safety and efficacy of ALDARA Cream have not been established for other types of basal cell carcinomas (BCC), including nodular and morpheaform (fibrosing or sclerosing) types. ALDARA Cream is not recommended for treatment of BCC subtypes other than the superficial variant (i.e., sBCC). Patients with sBCC treated with ALDARA Cream should have regular follow-up of the treatment site [see Clinical Studies (14.2)] .

The safety and efficacy of treating sBCC lesions on the face, head, and anogenital area have not been established.

5.6 Unevaluated Uses: External Genital Warts

ALDARA Cream has not been evaluated for the treatment of urethral, intravaginal, cervical, rectal, or intra-anal human papilloma viral disease.

6.1 Clinical Trials Experience: Actinic Keratosis

The data described below reflect exposure to ALDARA Cream or vehicle in 436 subjects enrolled in two double-blind, vehicle-controlled studies. Subjects applied ALDARA Cream or vehicle to a 25 cm 2contiguous treatment area on the face or scalp 2 times per week for 16 weeks.

Local skin reactions were collected independently of the adverse reaction "application site reaction" in an effort to provide a better picture of the specific types of local reactions that might be seen. The most frequently reported local skin reactions were erythema, flaking/scaling/dryness, and scabbing/crusting. The prevalence and severity of local skin reactions that occurred during controlled studies are shown in the following table.

The adverse reactions that most frequently resulted in clinical intervention (e.g., rest periods, withdrawal from study) were local skin and application site reactions. Overall, in the clinical studies, 2% (5/215) of subjects discontinued for local skin/application site reactions. Of the 215 subjects treated, 35 subjects (16%) on ALDARA Cream and 3 of 220 subjects (1%) on vehicle cream had at least one rest period. Of these ALDARA Cream subjects, 32 (91%) resumed therapy after a rest period.

In the AK studies, 22 of 678 (3.2%) of ALDARA-treated subjects developed treatment site infections that required a rest period off ALDARA Cream and were treated with antibiotics (19 with oral and 3 with topical).

Of the 206 ALDARA subjects with both baseline and 8-week post-treatment scarring assessments, 6 (2.9%) had a greater degree of scarring scores at 8 weeks post-treatment than at baseline.

6.2 Clinical Trials Experience: Superficial Basal Cell Carcinoma

The data described below reflect exposure to ALDARA Cream or vehicle in 364 subjects enrolled in two double-blind, vehicle-controlled studies. Subjects applied ALDARA Cream or vehicle 5 times per week for 6 weeks. The incidence of adverse reactions reported by >1% of subjects during the studies is summarized in Table 5.

The most frequently reported adverse reactions were local skin and application site reactions including erythema, edema, induration, erosion, flaking/scaling, scabbing/crusting, itching and burning at the application site. The incidence of application site reactions reported by > 1% of the subjects during the 6 week treatment period is summarized in Table 6.

Local skin reactions were collected independently of the adverse reaction "application site reaction" in an effort to provide a better picture of the specific types of local reactions that might be seen. The prevalence and severity of local skin reactions that occurred during controlled studies are shown in the following table.

The adverse reactions that most frequently resulted in clinical intervention (e.g., rest periods, withdrawal from study) were local skin and application site reactions; 10% (19/185) of subjects received rest periods. The average number of doses not received per subject due to rest periods was 7 doses with a range of 2 to 22 doses; 79% of subjects (15/19) resumed therapy after a rest period. Overall, in the clinical studies, 2% (4/185) of subjects discontinued for local skin/application site reactions.

In the sBCC studies, 17 of 1266 (1.3%) ALDARA-treated subjects developed treatment site infections that required a rest period and treatment with antibiotics.

6.3 Clinical Trials Experience: External Genital Warts

In controlled clinical trials for genital warts, the most frequently reported adverse reactions were local skin and application site reactions.

Some subjects also reported systemic reactions. Overall, 1.2% (4/327) of the subjects discontinued due to local skin/application site reactions. The incidence and severity of local skin reactions during controlled clinical trials are shown in Table 8.

Remote site skin reactions were also reported. The severe remote site skin reactions reported for females were erythema (3%), ulceration (2%), and edema (1%); and for males, erosion (2%), and erythema, edema, induration, and excoriation/flaking (each 1%).

Selected adverse reactions judged to be probably or possibly related to ALDARA Cream are listed in Table 9.

Adverse reactions judged to be possibly or probably related to ALDARA Cream and reported by more than 1% of subjects included:

Application Site Disorders:burning, hypopigmentation, irritation, itching, pain, rash, sensitivity, soreness, stinging, tenderness

Remote Site Reactions:bleeding, burning, itching, pain, tenderness, tinea cruris

Body as a Whole:fatigue, fever, influenza-like symptoms

Central and Peripheral Nervous System Disorders:headache

Gastrointestinal System Disorders:diarrhea

Musculoskeletal System Disorders:myalgia

6.4 Clinical Trials Experience: Dermal Safety Studies

Provocative repeat insult patch test studies involving induction and challenge phases produced no evidence that ALDARA Cream causes photoallergenicity or contact sensitization in healthy skin; however, cumulative irritancy testing revealed the potential for ALDARA Cream to cause irritation, and application site reactions were reported in the clinical studies [see Adverse Reactions (6)] .

6.5 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of ALDARA Cream. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Application Site Disorders:tingling at the application site

Body as a Whole:angioedema

Cardiovascular:capillary leak syndrome, cardiac failure, cardiomyopathy, pulmonary edema, arrhythmias (tachycardia, atrial fibrillation, palpitations), chest pain, ischemia, myocardial infarction, syncope

Endocrine:thyroiditis

Gastrointestinal System Disorders:abdominal pain

Hematological:decreases in red cell, white cell, and platelet counts (including idiopathic thrombocytopenic purpura), lymphoma

Hepatic:abnormal liver function

Infections and Infestations:herpes simplex

Musculoskeletal System Disorders:arthralgia

Neuropsychiatric:agitation, cerebrovascular accident, convulsions (including febrile convulsions), depression, insomnia, multiple sclerosis aggravation, paresis, suicide

Respiratory:dyspnea

Urinary System Disorders:proteinuria, dysuria, urinary retention

Skin and Appendages:exfoliative dermatitis, erythema multiforme, hyperpigmentation, hypertrophic scar

Vascular:Henoch-Schönlein purpura syndrome

8.1 Pregnancy

8.3 Nursing Mothers

It is not known whether imiquimod is excreted in human milk following use of ALDARA Cream. Because many drugs are excreted in human milk, caution should be exercised when ALDARA Cream is administered to nursing women.

8.4 Pediatric Use

AK and sBCC are not conditions generally seen within the pediatric population. The safety and efficacy of ALDARA Cream for AK or sBCC in patients less than 18 years of age have not been established.

Safety and efficacy in patients with external genital/perianal warts below the age of 12 years have not been established.

ALDARA Cream was evaluated in two randomized, vehicle-controlled, double-blind trials involving 702 pediatric subjects with molluscum contagiosum (MC) (470 exposed to ALDARA; median age 5 years, range 2–12 years). Subjects applied ALDARA Cream or vehicle 3 times weekly for up to 16 weeks. Complete clearance (no MC lesions) was assessed at Week 18. In Study 1, the complete clearance rate was 24% (52/217) in the ALDARA Cream group compared with 26% (28/106) in the vehicle group. In Study 2, the clearance rates were 24% (60/253) in the ALDARA Cream group compared with 28% (35/126) in the vehicle group. These studies failed to demonstrate efficacy.

Similar to the studies conducted in adults, the most frequently reported adverse reaction from 2 studies in children with molluscum contagiosum was application site reaction. Adverse events which occurred more frequently in ALDARA-treated subjects compared with vehicle-treated subjects generally resembled those seen in studies in indications approved for adults and also included otitis media (5% ALDARA vs. 3% vehicle) and conjunctivitis (3% ALDARA vs. 2% vehicle).

Erythema was the most frequently reported local skin reaction. Severe local skin reactions reported by ALDARA-treated subjects in the pediatric studies included erythema (28%), edema (8%), scabbing/crusting (5%), flaking/scaling (5%), erosion (2%), and weeping/exudate (2%).

Systemic absorption of imiquimod across the affected skin of 22 subjects aged 2 to 12 years with extensive MC involving at least 10% of the total body surface area was observed after single and multiple doses at a dosing frequency of 3 applications per week for 4 weeks. The investigator determined the dose applied, either 1, 2, or 3 packets per dose, based on the size of the treatment area and the subject's weight. The overall median peak serum drug concentrations at the end of Week 4 was between 0.26 and 1.06 ng/mL except in a 2-year old female who was administered 2 packets of study drug per dose, had a C maxof 9.66 ng/mL after multiple dosing. Children aged 2–5 years received doses of 12.5 mg (1 packet) or 25 mg (2 packets) of imiquimod and had median multiple-dose peak serum drug levels of approximately 0.2 or 0.5 ng/mL, respectively. Children aged 6–12 years received doses of 12.5 mg, 25 mg, or 37.5 mg (3 packets) and had median multiple dose serum drug levels of approximately 0.1, 0.15, or 0.3 ng/mL, respectively. Among the 20 subjects with evaluable laboratory assessments, the median WBC count decreased by 1.4*10 9/L and the median absolute neutrophil count decreased by 1.42*10 9/L.

8.5 Geriatric Use

Of the 215 subjects treated with ALDARA Cream in the AK clinical studies, 127 subjects (59%) were 65 years and older, while 60 subjects (28%) were 75 years and older. Of the 185 subjects treated with ALDARA Cream in the sBCC clinical studies, 65 subjects (35%) were 65 years and older, while 25 subjects (14%) were 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. No other clinical experience has identified differences in responses between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.

12.1 Mechanism of Action

The mechanism of action of ALDARA Cream in treating AK and sBCC lesions is unknown.

12.2 Pharmacodynamics

12.3 Pharmacokinetics

Systemic absorption of imiquimod across the affected skin of 58 subjects with AK was observed with a dosing frequency of 3 applications per week for 16 weeks. Mean peak serum drug concentrations at the end of Week 16 were approximately 0.1, 0.2, and 3.5 ng/mL for the applications to face (12.5 mg imiquimod, 1 single-use packet), scalp (25 mg, 2 packets), and hands/arms (75 mg, 6 packets), respectively.

The application surface area was not controlled when more than one packet was used. Dose proportionality was not observed. However, it appears that systemic exposure may be more dependent on surface area of application than amount of applied dose. The apparent half-life was approximately 10 times greater with topical dosing than the 2-hour apparent half-life seen following subcutaneous dosing, suggesting prolonged retention of drug in the skin. Mean urinary recoveries of imiquimod and metabolites combined were 0.08% and 0.15% of the applied dose in the group using 75 mg (6 packets) for males and females, respectively following 3 applications per week for 16 weeks.

Systemic absorption of imiquimod was observed across the affected skin of 12 subjects with genital/perianal warts, with an average dose of 4.6 mg. Mean peak drug concentration of approximately 0.4 ng/mL was seen during the study. Mean urinary recoveries of imiquimod and metabolites combined over the whole course of treatment, expressed as percent of the estimated applied dose, were 0.11% and 2.41% in the males and females, respectively.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

In an oral (gavage) rat carcinogenicity study, imiquimod was administered to Wistar rats on a 2X/week (up to 6 mg/kg/day) or daily (3 mg/kg/day) dosing schedule for 24 months. No treatment-related tumors were noted in the oral rat carcinogenicity study up to the highest doses tested in this study of 6 mg/kg administered 2X/week in female rats (87X MRHD based on weekly AUC comparisons), 4 mg/kg administered 2X/week in male rats (75X MRHD based on weekly AUC comparisons), or 3 mg/kg administered 7X/week to male and female rats (153X MRHD based on weekly AUC comparisons).

In a dermal mouse carcinogenicity study, imiquimod cream (up to 5 mg/kg/application imiquimod or 0.3% imiquimod cream) was applied to the backs of mice 3X/week for 24 months. A statistically significant increase in the incidence of liver adenomas and carcinomas was noted in high-dose male mice compared to control male mice (251X MRHD based on weekly AUC comparisons). An increased number of skin papillomas was observed in vehicle cream control group animals at the treated site only. The quantitative composition of the vehicle cream used in the dermal mouse carcinogenicity study is the same as the vehicle cream used for ALDARA Cream, minus the active moiety (imiquimod).

In a 52-week dermal photococarcinogenicity study, the median time to onset of skin tumor formation was decreased in hairless mice following chronic topical dosing (3X/week; 40 weeks of treatment followed by 12 weeks of observation) with concurrent exposure to UV radiation (5 days per week) with the ALDARA Cream vehicle alone. No additional effect on tumor development beyond the vehicle effect was noted with the addition of the active ingredient, imiquimod, to the vehicle cream.

Imiquimod revealed no evidence of mutagenic or clastogenic potential based on the results of five in vitrogenotoxicity tests (Ames assay, mouse lymphoma L5178Y assay, Chinese hamster ovary cell chromosome aberration assay, human lymphocyte chromosome aberration assay, and SHE cell transformation assay) and three in vivogenotoxicity tests (rat and hamster bone marrow cytogenetics assay and a mouse-dominant lethal test).

Daily oral administration of imiquimod to rats, throughout mating, gestation, parturition, and lactation, demonstrated no effects on growth, fertility or reproduction, at doses up to 87X MRHD based on AUC comparisons.

14.1 Actinic Keratosis

In two double-blind, vehicle-controlled clinical studies, 436 subjects with AK were randomized to treatment with either ALDARA Cream or vehicle cream 2 times per week for 16 weeks. The studies enrolled subjects with 4 to 8 clinically typical, visible, discrete, nonhyperkeratotic, nonhypertrophic AK lesions within a 25 cm 2contiguous treatment area on either the face or scalp. The 25 cm 2contiguous treatment area could be of any dimensions (e.g., 5 cm × 5 cm, 3 cm by 8.3 cm, 2 cm by 12.5 cm). Study subjects ranged from 37 to 88 years of age (median 66 years) and 55% had Fitzpatrick skin type I or II. All ALDARA-treated subjects were Caucasians.

On a scheduled dosing day, the study cream was applied to the entire treatment area prior to normal sleeping hours and left on for approximately 8 hours. Twice-weekly dosing was continued for a total of 16 weeks. The clinical response of each subject was evaluated 8 weeks after the last scheduled application of study cream. Efficacy was assessed by the complete clearance rate, defined as the proportion of subjects at the 8-week post-treatment visit with no (zero) clinically visible AK lesions in the treatment area. Complete clearance included clearance of all baseline lesions, as well as any new or subclinical AK lesions which appeared during therapy.

Complete and partial clearance rates are shown in Table 11. The partial clearance rate was defined as the percentage of subjects in whom 75% or more baseline AK lesions were cleared.

Subclinical AK lesions may become apparent in the treatment area during treatment with ALDARA Cream. During the course of treatment, 48% (103/215) of subjects experienced an increase in AK lesions relative to the number present at baseline within the treatment area. Subjects with an increase in AK lesions had a similar response to those with no increase in AK lesions.

14.2 Superficial Basal Cell Carcinoma

In two double-blind, vehicle-controlled clinical studies, 364 subjects with primary sBCC were treated with ALDARA Cream or vehicle cream 5 times per week for 6 weeks. Target tumors were biopsy-confirmed sBCC and had a minimum area of 0.5 cm 2and a maximum diameter of 2.0 cm (4.0 cm 2). Target tumors were not to be located within 1.0 cm of the hairline, or on the anogenital area or on the hands or feet, or to have any atypical features. The population ranged from 31–89 years of age (median 60 years) and 65% had Fitzpatrick skin type I or II. On a scheduled dosing day, study cream was applied to the target tumor and approximately 1 cm (about 1/3 inch) beyond the target tumor prior to normal sleeping hours, and 5 times per week dosing was continued for a total of 6 weeks. The target tumor area was clinically assessed 12 weeks after the last scheduled application of study cream. The entire target tumor was then excised and examined histologically for the presence of tumor.

Efficacy was assessed by the complete response rate defined as the proportion of subjects with clinical (visual) and histological clearance of the sBCC lesion at 12 weeks post-treatment. Of ALDARA-treated subjects, 6% (11/178) who had both clinical and histological assessments post-treatment, and who appeared to be clinically clear had evidence of tumor on excision of the clinically clear treatment area.

Data on composite clearance (defined as both clinical and histological clearance) are shown in Table 12.

A separate 5-year, open-label study was conducted to assess the recurrence of sBCC treated with ALDARA Cream applied once daily 5 days per week for 6 weeks. Target tumor inclusion criteria were the same as for the studies described above. At 12 weeks post-treatment, subjects were clinically evaluated for evidence of persistent sBCC (no histological assessment). Subjects with no clinical evidence of sBCC entered the long-term follow-up period. At the 12-week post-treatment assessment, 90% (163/182) of the subjects enrolled had no clinical evidence of sBCC at their target site and 162 subjects entered the long-term follow-up period for up to 5 years. Two-year (24-month) follow-up data are available from this study and are presented in Table 13.

14.3 External Genital Warts

In a double-blind, placebo-controlled clinical study, 209 otherwise healthy subjects 18 years and older with genital/perianal warts were treated with ALDARA Cream or vehicle control 3 times per week for a maximum of 16 weeks. The median baseline wart area was 69 mm 2(range 8 to 5525 mm 2). Subject accountability is shown in Figure 1.

Figure 1: Subject Accountability (External Genital Warts)

*The other subjects were either lost to follow-up or experienced recurrences.

Data on complete clearance are listed in Table 14. The median time to complete wart clearance was 10 weeks.

Avoid freezing.

Keep out of reach of children.

General Information: All Indications

ALDARA Cream should be used as directed by a physician [see Dosage and Administration (2)]. ALDARA Cream is for external use only. Contact with the eyes, lips, and nostrils should be avoided [see Indications and Usage (1)and Dosage and Administration (2)]. The treatment area should not be bandaged or otherwise occluded. Partially used packets should be discarded and not reused. The prescriber should demonstrate the proper application technique to maximize the benefit of ALDARA Cream therapy.

It is recommended that patients wash their hands before and after applying ALDARA Cream.

Local Skin Reactions: All Indications

Patients may experience local skin reactions during treatment with ALDARA Cream (even with normal dosing). Potential local skin reactions include erythema, edema, vesicles, erosions/ulcerations, weeping/exudate, flaking/scaling/dryness, and scabbing/crusting. These reactions can range from mild to severe in intensity and may extend beyond the application site onto the surrounding skin. Patients may also experience application site reactions such as itching and/or burning [see Adverse Reactions (6)].

Local skin reactions may be of such intensity that patients may require rest periods from treatment. Treatment with ALDARA Cream can be resumed after the skin reaction has subsided, as determined by the physician. Patients should contact their physician promptly if they experience any sign or symptom at the application site that restricts or prohibits their daily activity or makes continued application of the cream difficult.

Because of local skin reactions, during treatment and until healed, the treatment area is likely to appear noticeably different from normal skin. Localized hypopigmentation and hyperpigmentation have been reported following use of ALDARA Cream. These skin color changes may be permanent in some patients.

Systemic Reactions: All Indications

Patients may experience flu-like systemic signs and symptoms during treatment with ALDARA Cream (even with normal dosing). Systemic signs and symptoms may include malaise, fever, nausea, myalgias, and rigors [see Adverse Reactions (6)]. An interruption of dosing should be considered.

Patients Being Treated for Actinic Keratosis (AK)

Dosing is 2 times per week for a full 16 weeks, unless otherwise directed by the physician. However, the treatment period should not be extended beyond 16 weeks due to missed doses or rest periods [see Dosage and Administration (2.1)].

It is recommended that the treatment area be washed with mild soap and water 8 hours following ALDARA Cream application.

Most patients using ALDARA Cream for the treatment of AK experience erythema, flaking/scaling/dryness, and scabbing/crusting at the application site with normal dosing [see Adverse Reactions (6.1)].

Use of sunscreen is encouraged, and patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using ALDARA Cream [see Warnings and Precautions (5.3)].

Subclinical AK lesions may become apparent in the treatment area during treatment and may subsequently resolve [see Clinical Studies (14.1)].

Patients Being Treated for Superficial Basal Cell Carcinoma (sBCC)

Dosing is 5 times per week for a full 6 weeks, unless otherwise directed by the physician. However, the treatment period should not be extended beyond 6 weeks due to missed doses or rest periods [see Dosage and Administration (2.2)].

It is recommended that the treatment area be washed with mild soap and water 8 hours following ALDARA Cream application [see Dosage and Administration (2.2)].

Most patients using ALDARA Cream for the treatment of sBCC experience erythema, edema, induration, erosion, scabbing/crusting, and flaking/scaling at the application site with normal dosing [see Adverse Reactions (6.2)].

Use of sunscreen is encouraged, and patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using ALDARA Cream [see Warnings and Precautions (5.3)].

The clinical outcome of therapy can be determined after resolution of application site reactions and/or local skin reactions.

Patients with sBCC treated with ALDARA Cream should have regular follow-up to re-evaluate the treatment site [see Clinical Studies (14.2)].

Patients Being Treated for External Genital Warts

Dosing is 3 times per week to external genital/perianal warts. ALDARA Cream treatment should continue until there is total clearance of the genital/perianal warts or for a maximum of 16 weeks.

It is recommended that the treatment area be washed with mild soap and water 6–10 hours following ALDARA Cream application.

It is common for patients to experience local skin reactions such as erythema, erosion, excoriation/flaking, and edema at the site of application or surrounding areas. Most skin reactions are mild to moderate.

Sexual (genital, anal, oral) contact should be avoided while ALDARA Cream is on the skin. Application of ALDARA Cream in the vagina is considered internal and should be avoided. Female patients should take special care if applying the cream at the opening of the vagina because local skin reactions on the delicate moist surfaces can result in pain or severe swelling, and may cause difficulty in passing urine or inability to urinate.

Uncircumcised males treating warts under the foreskin should retract the foreskin and clean the area daily.

New warts may develop during therapy, as ALDARA Cream is not a cure.

The effect of ALDARA Cream on the transmission of genital/perianal warts is unknown.

ALDARA Cream may weaken condoms and vaginal diaphragms; therefore, concurrent use is not recommended.

Should severe local skin reaction occur, the cream should be removed by washing the treatment area with mild soap and water.

Manufactured for:

Valeant Pharmaceuticals North America LLC

Bridgewater, NJ 08807 USA

By:
3M Health Care Limited
Loughborough Leicestershire LE11 5SF, United Kingdom

U.S. Patent Number: 7,696,159

ALDARA is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.

© Valeant Pharmaceuticals North America LLC

Rev 04/2018
9415901
3100013750